Germany’s IQWiG finds first tumor-agnostic drug provides no added benefit
Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) this week said that Bayer’s Vitrakvi (larotrectinib), approved in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
